Streetbeat News

Analyst Ratings

IR

In the last quarter, Ingersoll Rand (NYSE:IR) has received mostly bullish analyst ratings, with an average price target of $66.56, a 7.93% increase from the previous average price target of $61.67. The ratings are based on the company's predicted future earnings and the predictability of its revenue streams.

Portfolio Pulse from Benzinga Insights

July 10, 2023 | 5:00 pm

AAN

FMC

JUPW

MOB

NBTX

TIVC

US stocks traded mostly higher with the Dow up 0.42% and the S&P 500 up 0.05%, while the NASDAQ fell 0.14%. Wholesale inventories in the US remained unchanged in May. Mobilicom Limited (NASDAQ:MOB) shares rose 81% after receiving a commercial scale purchase order from Teledyne-FLIR for drone production. Jupiter Wellness, Inc. (NASDAQ:JUPW) shares rose 38% after executing an Asset Purchase Agreement with GBB Drink Lab. Nanobiotix S.A. (NASDAQ:NBTX) shares rose 41% after entering into a license agreement with Janssen Pharmaceutical. Tivic Health Systems, Inc. (NASDAQ:TIVC) shares dropped 40% after pricing public offering of shares. The Aaron's Company, Inc. (NYSE:AAN) shares fell 12% after a downgrade from Loop Capital. FMC Corporation (NYSE:FMC) shares fell 10% after cutting its Q2 and 2023 guidance.

Portfolio Pulse from Lisa Levin

July 10, 2023 | 4:58 pm

PBLA

Panbela Therapeutics Inc's (NASDAQ:PBLA) Phase 3 ASPIRE trial for patients with untreated metastatic pancreatic ductal adenocarcinoma has been recommended to continue without modification by the independent Data Safety Monitoring Board (DSMB). The company is also planning a Phase 1 clinical trial for the second quarter of 2023 to evaluate Ivospemin in treating platinum-resistant ovarian cancer. HC Wainwright maintains a Buy rating and a price target of $16 for PBLA.

Portfolio Pulse from Vandana Singh

July 10, 2023 | 4:55 pm

IOVA

Iovance Biotherapeutics Inc announced regulatory and clinical updates related to its Phase 2 IOV-LUN-202 trial in post-anti-PD-1 non-small cell lung cancer (NSCLC). The FDA said that the design of the trial might be acceptable for accelerated approval of LN-145 TIL therapy for lung cancer patients. Iovance plans to enroll approximately 120 patients into the trial, with enrollment expected to be complete during 2H 2024. The FDA's Priority Review of the marketing application for lifileucel in advanced melanoma remains on track. HC Wainwright reiterates its Buy rating and $38 price target for Iovance.

Portfolio Pulse from Vandana Singh

July 10, 2023 | 4:50 pm

INFI

MEIP

MRK

Infinity Pharmaceuticals has announced further design features of its Phase 2 MARIO-8 study in Squamous Cell Cancer of the Head and Neck (SCCHN). The study is designed to optimize the dose of the oral drug candidate, eganelisib, in combination with Merck & Co Inc's Keytruda. The company has received FDA feedback and, pending final FDA review and subject to the successful close of the company's proposed merger with MEI Pharma Inc, preliminary safety and efficacy data are expected in the second half of 2024. A second leading independent proxy advisory firm, Glass, Lewis & Co, has recommended that stockholders of Infinity and MEI vote for the merger. INFI shares are up 19.80% at $0.24 on the last check Monday.

Portfolio Pulse from Vandana Singh

July 10, 2023 | 4:45 pm

T

A large bearish position on AT&T (NYSE:T) has been noticed on publicly available options history. Benzinga's options scanner spotted 11 options trades for AT&T, with 10 being puts and 1 call. The sentiment of these big-money traders is split between 27% bullish and 72% bearish. Whales have been targeting a price range from $15.0 to $22.0 for AT&T over the last 3 months. Barclays has maintained their Equal-Weight rating on AT&T, with a price target of $17.

Portfolio Pulse from Benzinga Insights

July 10, 2023 | 4:33 pm

LLY

Unusual options activity has been observed for Eli Lilly (NYSE:LLY), with a bearish stance taken by a large investor. The sentiment among these big-money traders is split between 13% bullish and 86% bearish. The whales have been targeting a price range from $340.0 to $660.0 for Eli Lilly over the last 3 months. Cantor Fitzgerald has downgraded its action to Overweight with a price target of $485 and maintained their Overweight rating with a price target of $550. Truist Securities downgraded its action to Buy with a price target of $430.

Portfolio Pulse from Benzinga Insights

July 10, 2023 | 4:33 pm

DAL

UAL

United Airlines Holdings Inc (UAL) shares are trading higher by 1.64% to $56.30 after Citigroup analyst Stephen Trent maintained the stock with a Buy and raised the price target from $70 to $75. UAL shares are also higher by 9.7% over the trailing month amid strength in travel stocks, following May CPI data. Airline stocks also saw strength in late June in sympathy with Delta Air Lines, Inc. (DAL) after the company raised its second-quarter and 2023 guidance at its Investor Day presentation.

Portfolio Pulse from Henry Khederian

July 10, 2023 | 4:29 pm

BTCUSD

ETHUSD

Vitalik Buterin, co-founder of Ethereum, suggested that Bitcoin needs to adopt scalable solutions like Ethereum to expand beyond just a payment system. He mentioned Optimism and Arbitrum as two prominent rollup examples that Bitcoin could learn from. Ethereum has transitioned from a proof-of-work to a proof-of-stake network, while experimenting with various Layer 2 solutions such as ZK-rollups and Plasma. Bitcoin's scalability has been improved by the Lightning Network and the advent of Bitcoin Ordinals.

Portfolio Pulse from Murtuza Merchant

July 10, 2023 | 4:29 pm

CLSD

HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on Clearside Biomedical (NASDAQ:CLSD) and maintained a $6 price target.

Portfolio Pulse from Benzinga Newsdesk

July 10, 2023 | 4:17 pm